Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multi-center Clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy(SDT) in Patients With Recurrent High Grade Glioma (HGG)

NCT05362409 is registered in ClinicalTrials.gov with Alpheus Medical, Inc. as lead sponsor.

NCT NCT05362409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05362409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multi-center Clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy(SDT) in Patients With Recurrent High Grade Glioma (HGG)
Lead sponsor
Alpheus Medical, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 29, 2022
Completion date
February 3, 2025
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

high grade glioma